Short communication · 4 Aug 2026
Conference abstractPublished 5 Sep 2022
Inhibition of cAMP signaling recovers congenital heart defects in Pde2A deficient mice and reverts oxidative stress
Sapienza University of Rome, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Phosphodiesterases (PDEs) are the enzymes that hydrolyze cyclic nucleotides (cAMP and cGMP) playing a key role in the homeostasis of these two secondary messengers. PDE2A is a dual-specific PDE that breaks down both cAMP and cGMP and can be activated by cGMP. It appears peculiar that the Pde2A-knockout (KO) mouse model is embryonically lethal, likely due to a strongly reduced size of liver and to a severe anemia. In addition, the heart of Pde2A-KO embryos shows ventricular and atrial septum defects, hypertrabeculation, heart dilatation and non-compaction defect. We recently highlighted a direct relationship between Pde2A impairment, consequent increase of cAMP and the onset of mouse congenital heart defects (CHDs), however the molecular mechanisms underlined the heart defects remain unknown. Methodology: Here, we carried-out the transcriptome of Pde2A-KO embryonic heart by RNA sequencing. We also tested in Pde2A-heterozygous pregnant females two drugs, Metoprolol and H89, that acting on cAMP signaling, rescue CHDs in Pde2AKO embryos. Findings: We found a significant modulation of more than 500 genes affecting biological processes involved in the immune system, cardiomyocyte development and contractility, angiogenesis, control of gene transcription and oxidative stress. The most altered genes common in different pathways were also analyzed by quantitative real time PCR confirming the RNA-seq data. Metoprolol and H89 were able to prevent heart dilatation and hypertabeculation. Metoprolol was also able to partially impede heart septum defect and oxidative stress at molecular levels. Conclusions: We identified specific biological processes, molecules and cell signaling that can be targeted by selected drugs with consequent beneficial effects for cAMP-dependent CHDs.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical and Experimental Cardiology.
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Manuela Pellegrini”

